E-LIB Suche - Ergebnisse für: Pratley, R.

1

Dynamic associations between glucose and ecological momenta..:

Hawks, Z. W. ; Beck, E. D. ; Jung, L....
npj Digital Medicine. 7 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

2

Baseline cardiovascular risk in subjects with type 2 diabet..:

Mahaffey, K W ; Baeres, F M M ; Bakris, G...
European Heart Journal. 43 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

3

IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN ..:

Verma, S. ; Bain, S. ; Honoré, J....
Canadian Journal of Cardiology. 35 (2019) 10 - p. S147 , 2019

Link: https://doi.org/10.1016/..

4

THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS LIRAGLUTIDE A..:

Leiter, L. ; Bain, S. ; Bhatt, D....
Canadian Journal of Cardiology. 35 (2019) 10 - p. S118-S119 , 2019

Link: https://doi.org/10.1016/..

5

Efficacité du semaglutide versus dulaglutide en fonction du..:

Guerci, B. ; Pratley, R. ; Frias, J.P....
Annales d'Endocrinologie. 79 (2018) 4 - p. 261 , 2018

Link: https://doi.org/10.1016/..

6

Risk of Major Cardiovascular Events in Patients With Type 2..:

Davis, T. ; Poulter, N. ; Bain, S....
Heart, Lung and Circulation. 27 (2018) - p. S344 , 2018

Link: https://doi.org/10.1016/..

7

Bénéfice du liraglutide dans la réduction des complications..:

Marre, M. ; Dhatariya, K. ; Bain, S....
Annales d'Endocrinologie. 79 (2018) 4 - p. 262 , 2018

Link: https://doi.org/10.1016/..

8

Étude LEADER - liraglutide et événements cardiovasculaires ..:

Marre, M. ; Gilbert, M.P. ; Bain, S.C....
Annales d'Endocrinologie. 79 (2018) 4 - p. 265-266 , 2018

Link: https://doi.org/10.1016/..

9

Risque d'événements cardiovasculaires majeurs chez les diab..:

Marre, M. ; Bouzidi, A. ; Poulter, N....
Annales d'Endocrinologie. 78 (2017) 4 - p. 398 , 2017

Link: https://doi.org/10.1016/..

10

RISK OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2..:

Leiter, L. ; Poulter, N. ; Bain, S....
Canadian Journal of Cardiology. 33 (2017) 10 - p. S126-S127 , 2017

Link: https://doi.org/10.1016/..

11

Cardiovascular safety of the dipetidyl peptidase‐4 inhibito..:

White, W. B. ; Pratley, R. ; Fleck, P....
Diabetes, Obesity and Metabolism. 15 (2013) 7 - p. 668-673 , 2013

Link: https://doi.org/10.1111/..

12

In T2D patients with baseline A1c <8.0%, liraglutide achiev..:

King, A. ; Montanya, E. ; Pratley, R....
Primary Care Diabetes. 7 (2013) 1 - p. 79 , 2013

Link: https://doi.org/10.1016/..

13

One year of liraglutide treatment offers sustained and more..:

Pratley, R. ; Nauck, M. ; Bailey, T....
International Journal of Clinical Practice. 65 (2011) 4 - p. 397-407 , 2011

Link: https://doi.org/10.1111/..

14

Liraglutide improves treatment satisfaction in people with ..:

Davies, M. ; Pratley, R. ; Hammer, M...
Diabetic Medicine. 28 (2011) 3 - p. 333-337 , 2011

Link: https://doi.org/10.1111/..

15

P279 - Liraglutide réduit plus efficacement l'HbA1c que la ..:

Courrege, J.-P. ; Davies, M. ; Pratley, R....
Diabetes & Metabolism. 37 (2011) 1 - p. A99 , 2011

Link: https://doi.org/10.1016/..